NX Prenatal today announced that it has entered into a strategic collaboration with Thermo Fisher Scientific. The collaboration is designed to expand upon integrated workflows that the companies have...
Read More »NX Prenatal to begin clinical trial of its exosome-based blood test for preterm birth risk
Samples from more than 2,300 pregnant patients will be evaluated to support commercialization of the Company's new maternal blood test targeted for use at 10-12 weeks of pregnancy; information at this early time point provides actionable results to the...
Read More »New study demonstrates the potential of NX Prenatal blood-based biomarker panel to identify risk of premature birth as early as week 10 of pregnancy
LOUISVILLE, Ky.March 22, 2016 – NX Prenatal, Inc. announced today that the American Journal of Obstetrics and Gynecology (“AJOG”) published a manuscript entitled, “Evaluation of proteomic biomarkers associated with circulating microparticles as an effective means to stratify the risk of spontaneous ...
Read More »